Ian Bilmon

Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of <i>FLT3</i>

Mark J. Levis, Mehdi Hamadani, Brent R. Logan et al. · Journal of Clinical Oncology · 2024 · 185 citations · Full text

Medicine, Hematology, Pharmacotherapy +11

Low-cost generation of Good Manufacturing Practice–grade CD19-specific chimeric antigen receptor–expressing T cells using piggyBac gene transfer and patient-derived materials

Saumya Ramanayake, Ian Bilmon, David Bishop et al. · Cytotherapy · 2015 · 91 citations

Life Sciences, Biotechnology, Immunology +15

Single-Agent High-Dose Cyclophosphamide for Graft-versus-Host Disease Prophylaxis in Human Leukocyte Antigen–Matched Reduced-Intensity Peripheral Blood Stem Cell Transplantation Results in an Unacceptably High Rate of Severe Acute Graft-versus-Host Disease

Kenneth F. Bradstock, Ian Bilmon, John Kwan et al. · Biology of Blood and Marrow Transplantation · 2015 · 64 citations

Medicine, Hematology, Immunology +17

Second cancer risk in adults receiving autologous haematopoietic SCT for cancer: a population-based cohort study

Ian Bilmon, Lesley J. Ashton, Renate E. Le Marsney et al. · Bone Marrow Transplantation · 2014 · 46 citations · Full text

Medicine, Hematology, Oncology +16

Influence of Stem Cell Source on Outcomes of Allogeneic Reduced-Intensity Conditioning Therapy Transplants Using Haploidentical Related Donors

Kenneth F. Bradstock, Ian Bilmon, John Kwan et al. · Biology of Blood and Marrow Transplantation · 2015 · 43 citations · Full text

Medicine, Hematology, Immunology +17